<DOC>
	<DOCNO>NCT02338934</DOCNO>
	<brief_summary>This single arm , open-labelled study determine effectiveness combination Cinacalcet Vitamin D analogue treatment severe hyperparathyroidism patient ESRF haemodialysis . Patients start PO Cinacalcet 25mg OD + PO/IV active Vitamin D analogue adjust increments/decrements step 1 mcg 3x per week every 1-4 week correct calcium level within 2.4-2.54 mmol/L . After iPTH reach 2-9x ULN , patient enters maintenance phase . If serum calcium fall 2.1mmol/L , active Vit D dose increase 2.54 mmol/L , dose decrease . Percentage reduction iPTH level baseline 6,12 24 month treatment Percentage patient achieve iPTH level within target range 2-9x upper limit normal 6 , 12 24 month determine</brief_summary>
	<brief_title>Cinacalcet Management Secondary Hyperparathyroidism Haemodialysis Patients</brief_title>
	<detailed_description>Many patient haemodialysis develop secondary hyperparathyroidism . Vitamin D analogues alphacalcidol need bring iPTH level normal . However , analogue cause hypercalcaemia , thus dose limited effect . Cinacalcet , currently widely available patient hospital , calcimimetic reduce iPTH serum calcium level . No study yet carry investigate outcome use low dos Cinacalcet mean optimize dos vitamin D analogue keep calcium level go upper limit . So single arm , open-labelled study design determine effectiveness combination Cinacalcet Vitamin D analogue treatment severe hyperparathyroidism patient ESRF haemodialysis . No formal sample size calculation do proof concept study . Power calculation do end base primary outcome study . Methodology : Patients start PO Cinacalcet 25mg OD + PO/IV active Vitamin D analogue adjust increments/decrements step 1 mcg 3x per week every 1-4 week correct calcium level within 2.4-2.54 mmol/L . After iPTH reach 2-9x ULN , patient enters maintenance phase . If serum calcium fall 2.1mmol/L , active Vit D dose increase 2.54 mmol/L , dose decrease . Percentage reduction iPTH level baseline 6,12 24 month treatment Percentage patient achieve iPTH level within target range 2-9x upper limit normal 6 , 12 24 month determine .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>1 . End Stage Renal Failure ( ESRF ) patient haemodialysis iPTH level 9x upper limit normal 2 . Patients history active Vitamin D analogue dos limit hypercalcaemia ( &gt; 2.54 mmol/L ) 1 . Pregnant breastfeed plan become pregnant 2 . Life expectancy 6 month less 3 . History decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>